KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $164.1 million.

  • Neogenomics' Cash & Current Investments fell 5768.14% to $164.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $164.1 million, marking a year-over-year decrease of 5768.14%. This contributed to the annual value of $386.8 million for FY2024, which is 683.02% down from last year.
  • As of Q3 2025, Neogenomics' Cash & Current Investments stood at $164.1 million, which was down 5768.14% from $163.7 million recorded in Q2 2025.
  • Neogenomics' Cash & Current Investments' 5-year high stood at $802.7 million during Q1 2021, with a 5-year trough of $163.7 million in Q2 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $415.2 million (2023), whereas its average is $428.4 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first surged by 83060.03% in 2021, then crashed by 5779.74% in 2025.
  • Over the past 5 years, Neogenomics' Cash & Current Investments (Quarter) stood at $515.4 million in 2021, then decreased by 15.02% to $438.0 million in 2022, then decreased by 5.2% to $415.2 million in 2023, then decreased by 6.83% to $386.8 million in 2024, then crashed by 57.58% to $164.1 million in 2025.
  • Its Cash & Current Investments stands at $164.1 million for Q3 2025, versus $163.7 million for Q2 2025 and $358.1 million for Q1 2025.